Bridgebio U-turn shows how money can be made twice over
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
Exact gatecrashes the liquid biopsy party
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
Illumina sees the light – or thinks it does
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Thermo Fisher buys Qiagen after all
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Antitrust watchdog plunges Illumina’s megamerger into darkness
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
Storm-tossed Qiagen plots a course to higher growth
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
